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Background
Platelets play a central role in haemostasis. Blood vessel
injury leads to platelet aggregation and also invokes an
inflammatory response leading to the formation of pros-
tanoids like prostaglandin E2 (PGE2) and prostacyclin
(PGI2). It is known that low concentrations of PGE2
enhance and high concentrations inhibit platelet aggrega-
tion. PGE2 mediates its effect through four receptors: EP1
(Gαq signalling), EP3 (three isoforms present; signals via
Gi, Gs or Gq based on cell type), EP2 and EP4 (Gs signal-
ling). PGI2 is known to inhibit platelet aggregation
through its IP receptor (Gs signalling). The role of EP3 in
exacerbating platelet aggregation has been well described.
However, the role of EP4 which acts via the same G protein
coupling like IP has not been explored in detail. The aim
of this study was to investigate the role of EP4 in platelet
aggregation.
Methods
Platelet aggregation assays were performed ex vivo using a
platelet aggregation analyser (Aggregometer II). Blood
from healthy human donors was used to obtain platelet-
rich plasma. Aggregation was induced using ADP or colla-
gen. Different agonists and antagonists were added to
investigate their effects on platelet aggregation. Ca2+ flux
changes caused by addition of agonists were also exam-
ined using a fluorescent Ca2+ dye (Fluo-3 AM) by flow
cytometry.
Results
As expected, PGE2 (up to 300 nM) and an EP3 agonist (sul-
prostone) enhanced platelet aggregation, whereas an EP2-
selective agonist (butaprost) seemed to have no effect on
platelet aggregation. On the contrary, an EP4 agonist
(ONO AE1-329) inhibited platelet aggregation in a con-
centration-dependent manner, and this effect could be
reversed by using EP4 antagonists (ONO AE3-208 and
GW627368x) but not an IP or a DP antagonist. Inhibition
of protein kinase C prevented the inhibitory effect of the
EP4 agonist, while inhibition of adenylate cyclase had no
effect. The EP4 agonist ONO AE1-329 also attenuated Ca2+
flux in platelets that had been stimulated with ADP.
Conclusion
These results are suggestive of an exclusive EP4 effect on
inhibition of platelet aggregation and EP4 could be a
potential target of antithrombotic therapy.
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